Lupin unveils Rufinamide Oral Suspension for seizure disorder in US
Mumbai: Global pharma major Lupin Limited today announced the launch of Rufinamide Oral Suspension, 40 mg/mL to market a generic equivalent of Banzel Oral Suspension, 40 mg/mL of Eisai Inc.
Rufinamide is used in combination with other therapy and medication for the treatment of Lennox–Gastaut syndrome and various other seizure disorders.
Rufinamide Oral Suspension (RLD Banzel) had estimated annual sales of USD 72 million in the U.S. (IQVIA MAT April 2023).
Medical Dialogues team had earlier reported that the company's wholly-owned subsidiary, Novel Laboratories Inc., based in Somerset, New Jersey, had received approval from the USFDA for its Abbreviated New Drug Application for Diazepam Rectal Gel, 10 mg and 20 mg, Rectal Delivery System.
Read also: Lupin arm Novel Labs bags USFDA nod for Diazepam Rectal Gel
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23.
Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
